Meaningful Clinical Changes in Alzheimer Disease Measured With the iADRS and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings-Reference-Cited by-同舟云学术

Meaningful Clinical Changes in Alzheimer Disease Measured With the iADRS and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings

Published:2023-04 Issue:2 Volume:13 Page:
ISSN:2163-0402
Container-title:Neurology Clinical Practice
language:en
Short-container-title:Neur Clin Pract

Author:

Wessels Alette M.¹,Dennehy Ellen B.¹,Dowsett Sherie A.¹,Dickson Samuel P.¹,Hendrix Suzanne B.¹

Affiliation:

1. Eli Lilly and Company (AMW, EBD, SAD), Indianapolis, IN; Department of Psychological Sciences (EBD), Purdue University, West Lafayette, IN; and Pentara Corporation (SPD, SBH), Millcreek, UT.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Neurology (clinical)

Link

https://www.neurology.org/doi/pdfdirect/10.1212/CPJ.0000000000200127

Reference26 articles.

1. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Early Alzheimer's Disease: Developing Drugs for Treatment Guidance for Industry. 2018. Accessed June 1, 2022. fda.gov/media/110903/download.

2. The Alzheimer’s Disease Assessment Scale-Cognitive-Plus (ADAS-Cog-Plus): an expansion of the ADAS-Cog to improve responsiveness in MCI

3. The ADAS‐Cog revisited: Novel composite scales based on ADAS‐Cog to improve efficiency in MCI and early AD trials

4. Development of a straightforward and sensitive scale for MCI and early AD clinical trials

5. ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessing the clinical meaningfulness of slowing CDR-SB progression with disease-modifying therapies for Alzheimer disease;2024-07-16

2. Meaningful benefit of disease‐modifying treatment: Evaluating changes in health‐related resource use;Alzheimer's & Dementia: Translational Research & Clinical Interventions;2024-07

3. Contextualising the benefits and risks of anti‐amyloid therapy for patients with Alzheimer disease and their care team;Medical Journal of Australia;2024-06-19

4. Donanemab in Japanese Patients with Early Alzheimer’s Disease: Subpopulation Analysis of the TRAILBLAZER-ALZ 2 Randomized Trial;Neurology and Therapy;2024-04-06

5. A Comprehensive Review on Potential Molecular Drug Targets for the Management of Alzheimer's Disease;Central Nervous System Agents in Medicinal Chemistry;2024-04